Funck, Jr. Robert E. 4
4 · ABBOTT LABORATORIES · Filed Feb 23, 2022
Insider Transaction Report
Form 4
Funck Robert E
Vice President, Controller
Transactions
- Award
Option (right to buy)
2022-02-18+133,670→ 133,670 totalExercise: $117.58From: 2023-02-18Exp: 2032-02-17→ Common Shares (133,670 underlying) - Award
Common shares without par value
2022-02-18+28,682→ 217,332 total
Holdings
- 10,000(indirect: By Trust)
Common shares without par value
- 10,000(indirect: By Trust)
Common shares without par value
- 18,085(indirect: By Trust)
Common shares without par value
- 500(indirect: By Daughter)
Common shares without par value
Footnotes (5)
- [F1]These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
- [F2]Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
- [F3]Balance in the Abbott Laboratories Stock Retirement Trust as of February 18, 2022.
- [F4]The reporting person disclaims beneficial ownership of all securities held by his daughter.
- [F5]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,556 on February 18, 2023, 44,557 on February 18, 2024, and 44,557 on February 18, 2025.